International AIDS Society Conference on HIV Science
Johnson & Johnson’s Brian Woodfall, M.D., was working at a Vancouver clinic in the mid-1990s. That’s where he met Tiko Kerr, who became one of the first patients to take the company’s HIV medicines—and has thrived to this day. For National AIDS Awareness Month, watch as Kerr, Dr. Woodfall and fellow researcher Joss J. De Wet, M.D., reflect on how those treatments have saved lives and continue to evolve, in this moving video.
“AIDS won’t stop for COVID-19": Meet 3 inspiring women who are as committed as ever to making HIV history
For World AIDS Day, three attendees of the virtual 2020 International AIDS Society Conference, including activist and actress Laverne Cox, talk about their groundbreaking work with HIV/AIDS in the midst of a global pandemic.
As the IAS Conference on HIV Science kicks off in Mexico City, we explain how an investigational HIV vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson works—and how researchers hope to help change lives around the world with it.
Announced ahead of the International AIDS Society Conference on HIV Science in Mexico City, the new study will evaluate an investigational vaccine regimen in eight countries around the world for its ability to protect people from HIV infection.
In the lead-up to the recent International AIDS Society Conference on HIV Science in the Netherlands, we sat down with Hanneke Schuitemaker, who’s hard at work on the holy grail of HIV research: a preventive treatment.